Singapore, September 1, 2018: A DRUG currently used to treat Chronic Myeloid Leukaemia (CML) will be available on the Pharmaceutical Benefits Scheme from today as a new treatment for another aggressive form of the disease. The drug, ICLUSIG (ponatinib) will now be available to all Philadelphia-positive Acute Lymphoblastic Leukaemia (Ph+ ALL) patients, who are intolerant
![Arctica Specialised Therapeutics](https://stabiopharma.com/wp-content/uploads/2021/03/stabio-logo.png)